Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Millennium Pharmaceuticals Inc patents


Recent patent applications related to Millennium Pharmaceuticals Inc. Millennium Pharmaceuticals Inc is listed as an Agent/Assignee. Note: Millennium Pharmaceuticals Inc may have other listings under different names/spellings. We're not affiliated with Millennium Pharmaceuticals Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "M" | Millennium Pharmaceuticals Inc-related inventors


Compounds and methods for inhibiting mitotic progression

This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.. ... Millennium Pharmaceuticals Inc

Administration of ubiquitin-activating enzyme inhibitor and chemotherapeutic agents

Disclosed are methods for the treatment of cancer in patients in need of such treatment. The methods comprise administering to such a patient an ubiquitin-activating enzyme (uae) inhibitor such as ((1r,2r,3s,4r)-2,3-dihydroxy-4-(2-(3-(tri-fluoromethylthio)phenyl)pyrazolo [1,5-a]pyrimidin-7-ylamino)cyclopentyl)methyl sulfamate (compound 1) or a pharmaceutically acceptable salt in combination with one or more chemotherapeutic agents. ... Millennium Pharmaceuticals Inc

Methods of treatment of cancer

. . The present invention provides a method of treating cancer with a proteasome inhibitor. The invention also provides a method of treating a patient with cancer based on elevated expression levels of nfκb, as measured by a h-score of the patients tumor sample using a nfκb p65 ihc assay. ... Millennium Pharmaceuticals Inc

Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase

Disclosed are methods for the treatment of proliferative disorders. Disclosed in particular, are methods for treatment of proliferative disorders such as cancer, by administering an mtorc1/2 inhibitor in combination with a selective inhibitor of aurora a kinase. ... Millennium Pharmaceuticals Inc

Proteasome inhibitors

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.. ... Millennium Pharmaceuticals Inc

Method for the prophylaxis or treatment of systemic lupus erythematosus and/or lupus nephritis

The present invention provides a method for the prophylaxis or treatment of systemic lupus erythematosus and/or lupus nephritis in a patient in need thereof, which comprises administering an effective amount of [(1r)-1-({[2,5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid or a citric acid ester thereof, or a pharmaceutically acceptable salt thereof to the patient.. . ... Millennium Pharmaceuticals Inc

Substituted pyrrolo[2,3-d]pyrimidines

This invention relates to compounds that inhibit e1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.. ... Millennium Pharmaceuticals Inc

Process for the synthesis of e1 activating enzyme inhibitors

The present invention provides processes and synthetic intermediates for the synthesis of 4-substituted ((4s, 2s, 4r)-2-hydroxy-4-{7h-pyrrolo[2,3-d]pyrimidin-7-yl}cyclopentyl)methyl sulfamates, which are e1 activating enzyme inhibitors, and are useful for the treatment of disorders of cell proliferation, particularly cancer, and other disorders associated with e1 activity.. . ... Millennium Pharmaceuticals Inc

Method of treating primary sclerosing cholangitis

Disclosed is a method for treating a subject having primary sclerosing cholangitis, comprising administering to said subject an effective amount of a humanized antibody or antigen-binding fragment thereof having binding specificity for alpha 4 beta 7 integrin.. . ... Millennium Pharmaceuticals Inc

Synthesis of boronic ester and acid compounds

The invention relates to the synthesis of boronic ester and acid compounds. More particularly, the invention provides improved synthetic processes for the large-scale production of boronic ester and acid compounds, including the peptide boronic acid proteasome inhibitor bortezomib.. ... Millennium Pharmaceuticals Inc

Novel crystalline form of a proteasome inhibitor

The present disclosure relates to a novel crystalline form of a proteasome inhibitor, and to the processes for the preparation thereof. The novel crystalline form according to the disclosure may be used in the preparation of pharmaceutical compositions for the treatment of cancer.. ... Millennium Pharmaceuticals Inc

Benzamides and related inhibitors of factor xa

Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor xa are described. Compositions containing such compounds are also described. ... Millennium Pharmaceuticals Inc

Quinazoline and quinoline compounds and uses thereof

This invention provides compounds of formula (i) or a pharmaceutically acceptable salt thereof, wherein t, j, r, r4, rq, o, ra, w and rb and subsets thereof are as described in the specification. The compounds are inhibitors of nampt and are thus useful for treating cancer, inflammatory conditions, and/or t-cell mediated autoimmune disease.. ... Millennium Pharmaceuticals Inc

Boronate ester compounds and pharmaceutical compositions thereof

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.. ... Millennium Pharmaceuticals Inc

12/21/17 / #20170360926

Predicting outcome of treatment with an anti-alpha4beta7 integrin antibody

. . The invention provides methods for treating patients with anti-α4β7 antibody comprising predicting outcome of the antibody therapy. The invention relates to the identification of patients who can respond to therapy comprising an anti-a4β7 antibody.. ... Millennium Pharmaceuticals Inc

12/07/17 / #20170349611

Derivatives of 1-amino-2-cyclobutylethylboronic acid

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.. ... Millennium Pharmaceuticals Inc

11/23/17 / #20170333434

Administration of ubiquitin-activating enzyme inhibitor and radiation

Disclosed are methods for the treatment of cancer in patients in need of such treatment. The methods comprise administering to such a patient an ubiquitin-activating enzyme (uae) inhibitor such as ((1r,2r,3s,4r)-2,3-dihydroxy-4-(2-(3-(trifluoromethylthio) phenyl)pyrazolo[1,5-a]pyrimidin-7-ylamino)cyclopentyl)methyl sulfamate (compound 1) or a pharmaceutically acceptable salt in combination with radiation. ... Millennium Pharmaceuticals Inc

11/16/17 / #20170327584

Vedolizumab for the treatment of fistulizing crohn's disease

A method for treating a human patient suffering from fistulizing crohn's disease, comprising administering to a patient suffering from fistulizing crohn's disease, a humanized antibody having binding specificity for human α4β7 integrin, wherein the human patient has a seton that was surgically placed prior to administration of the antibody, and wherein the dosing regimen induces fistula(e) healing.. . ... Millennium Pharmaceuticals Inc

11/16/17 / #20170326119

Novel pharmaceutical salts and polymorphs of a factor xa inhibitor

The present invention provides for salts comprising a compound of formula i and an acid that has activity against mammalian factor xa. The present invention is also directed to methods of making the compound of formula i.. ... Millennium Pharmaceuticals Inc

10/05/17 / #20170281551

Solid pharmaceutical compositions and processes for their production

This invention provides novel solid pharmaceutical compositions and processes for the bulk production of said compositions. This invention also provides methods of using the pharmaceutical compositions in the treatment of cancer.. ... Millennium Pharmaceuticals Inc

06/22/17 / #20170174704

Quinoxaline compounds and uses thereof

. . . . . . This invention provides compounds of formula i and subsets thereof: wherein t, j, r, r4, rq, o, ra, and rb and subsets thereof are as described in the specification. The compounds are inhibitors of nampt and are thus useful for treating cancer, inflammatory conditions, or t-cell mediated autoimmune disease.. ... Millennium Pharmaceuticals Inc

06/22/17 / #20170173033

Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use

The invention relates to a pharmaceutical composition comprising compound 1 or a pharmaceutically acceptable salt thereof for the treatment of cancer and a process for its preparation. The invention also relates to administering the pharmaceutical composition to a patient according to an intermittent dosing regimen.. ... Millennium Pharmaceuticals Inc

06/08/17 / #20170157155

Method of treatment of nasopharyngeal cancer

The present invention provides a method of treating nasopharyngeal cancer with a proteasome inhibitor of formula (7). The invention also provides a method of treating a patient with nasopharyngeal cancer based on elevated expression levels of nfkb, as measured by a h-score of the patient's nasopharyngeal cancer tumor sample using a “nfkb p65 ihc assay. ... Millennium Pharmaceuticals Inc

05/18/17 / #20170136024

Inhibitors of e1 activating enzymes

This invention relates to compounds that inhibit e1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.. ... Millennium Pharmaceuticals Inc

04/20/17 / #20170107579

E1 enzyme mutants and uses thereof

The invention provides isolated nucleic acids molecules, designated uba3, uae, or uba6, or other e1 enzyme variant nucleic acid molecules, which encode novel e1 enzyme variant proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing uba3, uae, or uba6, or other e1 enzyme variant nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a uba3, uae, or uba6, or other e1 enzyme variant gene has been introduced or disrupted. ... Millennium Pharmaceuticals Inc

03/23/17 / #20170081413

Antibodies which bind human cxcr3

Antibodies and antigen-binding fragments of antibodies that bind human cxcr3 are disclosed. In preferred embodiments, the antibodies are human. ... Millennium Pharmaceuticals Inc

02/23/17 / #20170050935

Heteroaryl compounds useful as inhibitors of e1 activating enzymes

. . This invention relates to compounds that inhibit e1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.. ... Millennium Pharmaceuticals Inc

02/09/17 / #20170037151

Anti-psyk antibody molecules and use of same for syk-targeted therapy

The invention relates to antibody molecules which bind psyk, and methods for using the same for diagnosis, prognosis, to select patients for treatment with a syk-targeted therapy, or evaluate the pharmacodynamic profile of a syk-targeted therapy.. . ... Millennium Pharmaceuticals Inc

02/09/17 / #20170035917

Methods of treatment of cancer

The present invention provides a method of treating cancer with a proteasome inhibitor. The invention provides a method for treating a patient with a proteasome inhibitor based on measurements of tumor features using biomedical imaging techniques. ... Millennium Pharmaceuticals Inc

01/26/17 / #20170023577

Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy

The present invention is directed to the identification of markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with responsiveness or non-responsiveness to a therapeutic regimen comprising proteasome inhibition. ... Millennium Pharmaceuticals Inc

01/05/17 / #20170002078

Formulation for anti-alpha4beta7 antibody

Methods for inducing clinical remission of ulcerative colitis in a human patient are described comprising administration of an antibody that has binding specificity for human α4β7 integrin using a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.. . ... Millennium Pharmaceuticals Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Millennium Pharmaceuticals Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Millennium Pharmaceuticals Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###